Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 29,500 shares, a decline of 28.9% from the February 13th total of 41,500 shares. Based on an average daily volume of 56,600 shares, the short-interest ratio is presently 0.5 days. Currently, 2.4% of the shares of the company are short sold.

Cadrenal Therapeutics Trading Up 1.0 %

Shares of NASDAQ:CVKD traded up $0.20 on Monday, reaching $19.29. 37,133 shares of the company’s stock were exchanged, compared to its average volume of 38,893. Cadrenal Therapeutics has a twelve month low of $5.40 and a twelve month high of $22.90. The company has a fifty day moving average of $18.31 and a 200-day moving average of $15.14. The company has a market capitalization of $34.39 million, a price-to-earnings ratio of -2.89 and a beta of 1.40.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($2.74) earnings per share for the quarter, missing the consensus estimate of ($1.71) by ($1.03). As a group, equities research analysts forecast that Cadrenal Therapeutics will post -7.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Geode Capital Management LLC purchased a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned 0.59% of Cadrenal Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.